T03
Idiopathic Pulmonary Fibrosis
Key Facts
About Treamid Therapeutics
Treamid Therapeutics is a private, preclinical-stage biotech developing small molecule drugs for fibrotic and inflammatory conditions. Its lead asset, T03, has completed a Phase 1a study and is positioned for idiopathic pulmonary fibrosis (IPF), with additional exploratory programs in liver and renal fibrosis. The company operates with a lean model, leveraging collaborations with academic institutions and CROs while maintaining an in-house research lab to drive its discovery efforts forward.
View full company profileAbout Treamid Therapeutics
Treamid Therapeutics is a private, preclinical-stage biotech developing small molecule drugs for fibrotic and inflammatory conditions. Its lead asset, T03, has completed a Phase 1a study and is positioned for idiopathic pulmonary fibrosis (IPF), with additional exploratory programs in liver and renal fibrosis. The company operates with a lean model, leveraging collaborations with academic institutions and CROs while maintaining an in-house research lab to drive its discovery efforts forward.
View full company profileAbout Treamid Therapeutics
Treamid Therapeutics is a private, preclinical-stage biotech developing small molecule drugs for fibrotic and inflammatory conditions. Its lead asset, T03, has completed a Phase 1a study and is positioned for idiopathic pulmonary fibrosis (IPF), with additional exploratory programs in liver and renal fibrosis. The company operates with a lean model, leveraging collaborations with academic institutions and CROs while maintaining an in-house research lab to drive its discovery efforts forward.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| BIO 300 | Humanetics Corp. | Research |
| Undisclosed | Biossil | Phase 2/3 |
| KITCL27 | Kither Biotech | Preclinical |
| BRS101 | BreStem Therapeutics | Phase 1 |
| ING-006 | Innosphera Pharma | Preclinical |
| MNM‑siRNA IPF | Interna TX | Preclinical |
| Pirfenidone | Gyre Therapeutics | Marketed |
| PIPE-791 | Contineum Therapeutics | Phase 1 |